Некоторые особенности коррекции дисфункции жировой ткани

Некоторые особенности коррекции дисфункции жировой ткани

Автор: Филинюк П.Ю., Шишкин А.Н., Пчелин И.Ю., Худякова Н.В., Воловникова В.А., Кулибаба Т.Г.

Журнал: Juvenis scientia @jscientia

Рубрика: Обзорные статьи

Статья в выпуске: 6 т.9, 2023 года.

Бесплатный доступ

Стремительное распространение ожирения и ассоциированных с ним сердечно-сосудистых заболеваний вызывает серьёзную обеспокоенность в научно-медицинской сфере. Несмотря на многообразные подходы к решению данных проблем, до сих пор отсутствуют видимые успехи в борьбе с ожирением на популяционном уровне, а кардиоваскулярная патология всё ещё остаётся одной из главных причин смертности и инвалидизации в мире. Это ведёт к закономерным попыткам найти новые терапевтические пути. Одним из таких направлений может стать таргетная фармакологическая терапия дисфункции жировой ткани. Данная статья посвящена обзору эффектов таких адипоцитокинов, как адипонектин и лептин, одних из самых хорошо изученных маркеров нарушения функционирования жировой ткани, а также некоторых современных подходов к медикаментозной коррекции их влияний на сердечно-сосудистую систему. Проведённый анализ данных показывает, что гипоадипонектинемия и гиперлептинемия в сочетании с лептинорезистентностью ассоциируются с кардиоваскулярными заболеваниями и неблагоприятным прогнозом, а коррекция патологически изменённых уровней вышеупомянутых адипоцитокинов с достижением их оптимального соотношения может являться значимой терапевтической целью.

Еще

Сердечно-сосудистые заболевания, ожирение, адипоцитокины, адипонектин, лептин

Короткий адрес: https://sciup.org/14129343

IDR: 14129343   |   DOI: 10.32415/jscientia_2023_9_6_6-17

Список литературы Некоторые особенности коррекции дисфункции жировой ткани

  • Birsoy K, Festuccia WT, Laplante M. A comparative perspective on lipid storage in animals. J Cell Sci. 2013;126(Pt 7):1541-1552. DOI: 10.1242/jcs.104992
  • Neel JV. The “thrifty genotype” in 1998. Nutr Rev. 1999;57(5 Pt 2):S2-S9. DOI: 10.1111/j.1753-4887.1999.tb01782.x
  • Дедов И.И., Мокрышева Н.Г., Мельниченко Г.А. и др. Ожирение. Клинические рекомендации // Consilium Medicum. 2021. Т. 23, № 4. С. 311-325. [Dedov II, Mokrysheva NG, Mel’nichenko GA, et al. Obesity. Clinical guidelines. Consilium Medicum. 2021;23(4):311-325 (in Russ.)]. DOI: 10.26442/20751753.2021.4.200832. EDN: GYUVLJ
  • Samocha-Bonet D, Dixit VD, Kahn CR, et al. Metabolically healthy and unhealthy obese — the 2013 Stock Conference report. Obes Rev. 2014;15(9):697-708. DOI: 10.1111/obr.12199
  • Wronkowitz N, Romacho T, Sell H, Eckel J. Adipose tissue dysfunction and inflammation in cardiovascular disease. Front Horm Res. 2014;43:79-92. DOI: 10.1159/000360560
  • Шишкин А.Н., Князева А.И. Эндотелиальная дисфункция у больных с ожирением // Регионарное кровообращение и микроциркуляция. 2022. Т. 21, № 3(83). С. 4-11. [Shishkin AN, Kniazeva AI. Endothelial dysfunction in patients with obesity. Regional Blood Circulation and Microcirculation. 2022;21(3):4-11. (In Russ.)]. DOI: 10.24884/1682-6655-2022-21-3-4-11. EDN: LLAGEC
  • Трошина Е.А., Ершова Е.В. Фармакотерапия ожирения: что нового? // Проблемы эндокринологии. 2018. Т. 64, №4. С. 270-276. [Troshina EA, Ershova EV. Pharmacotherapy of obesity: what’s new? Problems of Endocrinology. 2018;64(4):270-276 (In Russ.)]. DOI: 10.14341/probl9315. EDN: YLICUP
  • Kelly T, Yang W, Chen CS, et al. Global burden of obesity in 2005 and projections to 2030. Int J Obes (Lond). 2008;32(9):1431-1437. DOI: 10.1038/ijo.2008.102
  • Longo M, Zatterale F, Naderi J, et al. Adipose Tissue Dysfunction as Determinant of Obesity-Associated Metabolic Complications. Int J Mol Sci. 2019;20(9):2358. DOI: 10.3390/ijms20092358
  • Fang H, Judd RL. Adiponectin Regulation and Function. Compr Physiol. 2018;8(3):1031-1063. DOI: 10.1002/cphy.c170046
  • Natarajan R, Salloum FN, Fisher BJ, et al. Hypoxia inducible factor-1 upregulates adiponectin in diabetic mouse hearts and attenuates post-ischemic injury. J Cardiovasc Pharmacol. 2008;51(2):178-187. DOI: 10.1097/FJC.0b013e31815f248d
  • Yamauchi T, Iwabu M, Okada-Iwabu M, et al. Adiponectin receptors: a review of their structure, function and how they work. Best Pract Res Clin Endocrinol Metab. 2014;28(1):15-23. DOI: 10.1016/j.beem.2013.09.003
  • Del Turco S, Navarra T, Gastaldelli A, Basta G. Protective role of adiponectin on endothelial dysfunction induced by AGEs: a clinical and experimental approach. Microvasc Res. 2011;82(1):73-76. DOI: 10.1016/j.mvr.2011.03.003
  • Berg AH, Combs TP, Scherer PE. ACRP30/adiponectin: an adipokine regulating glucose and lipid metabolism. Trends Endocrinol Metab. 2002;13(2):84-89. DOI: 10.1016/s1043-2760(01)00524-0
  • Pischon T, Girman CJ, Hotamisligil GS, et al. Plasma adiponectin levels and risk of myocardial infarction in men. JAMA. 2004;291(14):1730-1737. DOI: 10.1001/jama.291.14.1730
  • Shams M, Rasekhi Kazerouni A, Ostovan MA, Omrani GR. The relationship between serum adiponectin levels with the presence and severity of coronary artery disease. Arch Iran Med. 2012;15(10):611-616.
  • Costacou T, Zgibor JC, Evans RW, et al. The prospective association between adiponectin and coronary artery disease among individuals with type 1 diabetes. The Pittsburgh Epidemiology of Diabetes Complications Study. Diabetologia. 2005;48(1):41-48. DOI: 10.1007/s00125-004-1597-y
  • Chen MP, Tsai JC, Chung FM, et al. Hypoadiponectinemia is associated with ischemic cerebrovascular disease. Arterioscler Thromb Vasc Biol. 2005;25(4):821-826. DOI: 10.1161/01.ATV.0000157784.25920.a7
  • Efstathiou SP, Tsioulos DI, Tsiakou AG, et al. Plasma adiponectin levels and five-year survival after first-ever ischemic stroke. Stroke. 2005;36(9):1915-1919. DOI: 10.1161/01.STR.0000177874.29849.f0
  • Shibata R, Ouchi N, Ito M, et al. Adiponectin-mediated modulation of hypertrophic signals in the heart. Nat Med. 2004;10(12):1384-1389. DOI: 10.1038/nm1137
  • Liao Y, Takashima S, Maeda N, et al. Exacerbation of heart failure in adiponectin-deficient mice due to impaired regulation of AMPK and glucose metabolism. Cardiovasc Res. 2005;67(4):705-713. DOI: 10.1016/j.cardiores.2005.04.018
  • Buechler C, Haberl EM, Rein-Fischboeck L, Aslanidis C. Adipokines in Liver Cirrhosis. Int J Mol Sci. 2017;18(7):1392. DOI: 10.3390/ijms18071392
  • Kistorp C, Faber J, Galatius S, et al. Plasma adiponectin, body mass index, and mortality in patients with chronic heart failure. Circulation. 2005;112(12):1756-1762. DOI: 10.1161/CIRCULATIONAHA.104.530972
  • Kanaya AM, Wassel Fyr C, Vittinghoff E, et al. Serum adiponectin and coronary heart disease risk in older Black and White Americans. J Clin Endocrinol Metab. 2006;91(12):5044-5050. DOI: 10.1210/jc.2006-0107
  • Вербовой А.Ф., Митрошина Е.В., Шаронова Л.А. Адипокины и сердечно-сосудистые заболевания // Фарматека. 2015. № 5(298). С. 38-43. [Verbovoi AF, Mitroshina EV, Sharonova LA. Adipokiny i serdechno-sosudistye zabolevaniya (Adipokines and cardiovascular disease). Farmateka. 2015;(5):38-43. (in Russ.)]. EDN: TRVBZL
  • Sahebkar A, Watts GF. Fibrate therapy and circulating adiponectin concentrations: a systematic review and meta-analysis of randomized placebo-controlled trials. Atherosclerosis. 2013;230(1):110-120. DOI: 10.1016/j.atherosclerosis.2013.06.026
  • Yamauchi T, Kamon J, Waki H, et al. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med. 2001;7(8):941-946. DOI: 10.1038/90984
  • Combs TP, Wagner JA, Berger J, et al. Induction of adipocyte complement-related protein of 30 kilodaltons by PPARgamma agonists: a potential mechanism of insulin sensitization. Endocrinology. 2002;143(3):998-1007. DOI: 10.1210/endo.143.3.8662
  • Saleh S, El-Maraghy N, Reda E, Barakat W. Modulation of diabetes and dyslipidemia in diabetic insulin-resistant rats by mangiferin: role of adiponectin and TNF-α. An Acad Bras Cienc. 2014;86(4):1935-1948. DOI: 10.1590/0001-3765201420140212
  • Kawano J, Arora R. The role of adiponectin in obesity, diabetes, and cardiovascular disease. J Cardiometab Syndr. 2009;4(1):44-49. DOI: 10.1111/j.1559-4572.2008.00030.x
  • Grossini E, Prodam F, Walker GE, et al. Effect of monomeric adiponectin on cardiac function and perfusion in anesthetized pig. J Endocrinol. 2014;222(1):137-149. DOI: 10.1530/JOE-14-0170
  • Okada-Iwabu M, Yamauchi T, Iwabu M, et al. A small-molecule AdipoR agonist for type 2 diabetes and short life in obesity. Nature. 2013;503(7477):493-499. DOI: 10.1038/nature12656
  • Zhang N, Wei WY, Liao HH, et al. AdipoRon, an adiponectin receptor agonist, attenuates cardiac remodeling induced by pressure overload. J Mol Med (Berl). 2018;96(12):1345-1357. DOI: 10.1007/s00109-018-1696-8
  • Liu Y, Vu V, Sweeney G. Examining the Potential of Developing and Implementing Use of Adiponectin-Targeted Therapeutics for Metabolic and Cardiovascular Diseases. Front Endocrinol (Lausanne). 2019;10:842. DOI: 10.3389/fendo.2019.00842
  • Zhang Y, Proenca R, Maffei M, et al. Positional cloning of the mouse obese gene and its human homologue. Nature. 1994;372(6505):425-432. DOI: 10.1038/372425a0
  • Park HK, Ahima RS. Physiology of leptin: energy homeostasis, neuroendocrine function and metabolism. Metabolism. 2015;64(1):24-34. DOI: 10.1016/j.metabol.2014.08.004
  • Papathanasiou AE, Nolen-Doerr E, Farr OM, Mantzoros CS. GEOFFREY HARRIS PRIZE LECTURE 2018: Novel pathways regulating neuroendocrine function, energy homeostasis and metabolism in humans. Eur J Endocrinol. 2019;180(2):R59-R71. DOI: 10.1530/EJE-18-0847
  • Matsuda M, Kawasaki F, Inoue H, et al. Possible contribution of adipocytokines on diabetic neuropathy. Diabetes Res Clin Pract. 2004;66 Suppl 1:S121-S123. DOI: 10.1016/j.diabres.2004.05.010
  • Thorsell A, Mathé AA. Neuropeptide Y in Alcohol Addiction and Affective Disorders. Front Endocrinol (Lausanne). 2017;8:178. DOI: 10.3389/fendo.2017.00178
  • Kelesidis T, Kelesidis I, Chou S, Mantzoros CS. Narrative review: the role of leptin in human physiology: emerging clinical applications. Ann Intern Med. 2010;152(2):93-100. DOI: 10.7326/0003-4819-152-2-201001190-00008
  • Polyzos SA, Mantzoros CS. Leptin in health and disease: facts and expectations at its twentieth anniversary. Metabolism. 2015;64(1):5-12. DOI: 10.1016/j.metabol.2014.10.017
  • Осипова А.А. Роль лептина в регуляции энергетического обмена и функционировании организмов живой природы // Окружающая среда и энерговедение. 2019. № 2(2). С. 55-82. [Osipova AA. The role of leptin in the regulation of energy metabolism and the functioning of living organisms. Journal of Environmental Earth and Еnergy Study. 2019;(2):55-82. (In Russ.)] DOI: 10.5281/zenodo.3328788. EDN: XMYVEF
  • Aizawa-Abe M, Ogawa Y, Masuzaki H, et al. Pathophysiological role of leptin in obesity-related hypertension. J Clin Invest. 2000;105(9):1243-1252. DOI: 10.1172/JCI8341
  • Бородкина Д.А., Груздева О.В., Акбашева О.Е. и др. Лептинорезистентность, нерешённые вопросы диагностики // Проблемы эндокринологии. 2018. Т. 64, № 1. С. 62-66. [Borodkina DA, Gruzdeva OV, Akbasheva OE, et al. Leptin resistance: unsolved diagnostic issues. Problems Of Endocrinology. 2018;64(1):62-66. (in Russ.)]. DOI: 10.14341/probl8740. EDN: YVFZXX
  • Banks WA, DiPalma CR, Farrell CL. Impaired transport of leptin across the blood-brain barrier in obesity. Peptides. 1999;20(11):1341-1345. DOI: 10.1016/s0196-9781(99)00139-4
  • Schaab M, Kratzsch J. The soluble leptin receptor. Best Pract Res Clin Endocrinol Metab. 2015;29(5):661-670. DOI: 10.1016/j.beem.2015.08.002
  • Groba C, Mayerl S, van Mullem AA, et al. Hypothyroidism compromises hypothalamic leptin signaling in mice. Mol Endocrinol. 2013;27(4):586-597. DOI: 10.1210/me.2012-1311
  • Nejati-Koshki K, Akbarzadeh A, Pourhasan-Moghaddam M, et al. Inhibition of leptin and leptin receptor gene expression by silibinin-curcumin combination. Asian Pac J Cancer Prev. 2014;14(11):6595-6599. DOI: 10.7314/apjcp.2013.14.11.6595
  • Чёрная А., Камышанская И.Г., Пчелин И.Ю. Физиологическое и патологическое значение перикардиального жира для сердца и прилежащих сосудов // Juvenis scientia. 2022. Т. 8. № 1. С. 32-41. [Chiornaya A, Kamyshanskaya IG, Pchelin IY. Physiological and pathological significance of pericardial fat for the heart and adjacent vessels. Juvenis scientia. 2022;8(1):32-41 (in Russ)]. DOI: 10.32415/jscientia_2022_8_1_32-41. EDN: JZAEYE
  • Груздева О.В., Акбашева О.Е., Дылев Ю.А. и др. Адипокиновый и цитокиновый профили эпикардиальной и подкожной жировой ткани у пациентов с ишемической болезнью сердца // Бюллетень экспериментальной биологии и медицины. 2017. Т. 163, № 5. С. 560-563. [Gruzdeva OV, Akbasheva OE, Dyleva YA, et al. Adipokine and cytokine profiles of epicardial and subcutaneous adipose tissue in patients with coronary heart disease. Bulletin of Experimental Biology and Medicine. 2017;163(5):560-563 (in Russ.)]. DOI: 10.1007/s10517-017-3860-5. EDN: YRSVGD
  • Margetic S, Gazzola C, Pegg GG, Hill RA. Leptin: a review of its peripheral actions and interactions. Int J Obes Relat Metab Disord. 2002;26(11):1407-1433. DOI: 10.1038/sj.ijo.0802142
  • Xu FP, Chen MS, Wang YZ, et al. Leptin induces hypertrophy via endothelin-1-reactive oxygen species pathway in cultured neonatal rat cardiomyocytes. Circulation. 2004;110(10):1269-1275. DOI: 10.1161/01.CIR.0000140766.52771.6D
  • Shankar A, Xiao J. Positive relationship between plasma leptin level and hypertension. Hypertension. 2010;56(4):623-628. DOI: 10.1161/hypertensionaha.109.148213
  • Vega GL, Grundy SM. Metabolic risk susceptibility in men is partially related to adiponectin/leptin ratio. J Obes. 2013;2013:409679. DOI: 10.1155/2013/409679
  • Zeidan A, Purdham DM, Rajapurohitam V, et al. Leptin induces vascular smooth muscle cell hypertrophy through angiotensin II- and endothelin-1-dependent mechanisms and mediates stretch-induced hypertrophy. J Pharmacol Exp Ther. 2005;315(3):1075-1084. DOI: 10.1124/jpet.105.091561
  • Nalini D, Karthick R, Shirin V, et al. Role of the adipocyte hormone leptin in cardiovascular diseases - a study from Chennai based Population. Thromb J. 2015;13:12. DOI: 10.1186/s12959-015-0042-4
  • Чаулин А.М. Роль лептина в патогенезе атеросклероза: акцент на взаимодействии лептина с макрофагами // Научное обозрение. Биологические науки. 2021. № 3. С. 5-10. [Chaulin AM. The role of leptin in the pathogenesis of atherosclerosis: emphasis on the interaction of leptin with macrophages. Scientific Review. Biological science. 2021;(3):5-10. (in Russ.)]. DOI: 10.17513/srbs.1228. EDN: WIFFIG
  • Polyzos SA, Kountouras J, Zavos C, Deretzi G. The potential adverse role of leptin resistance in nonalcoholic fatty liver disease: a hypothesis based on critical review of the literature. J Clin Gastroenterol. 2011;45(1):50-54. DOI: 10.1097/MCG.0b013e3181ec5c66
  • Hall ME, Harmancey R, Stec DE. Lean heart: Role of leptin in cardiac hypertrophy and metabolism. World J Cardiol. 2015;7(9):511-524. DOI: 10.4330/wjc.v7.i9.511
  • Pieterse C, Schutte R, Schutte AE. Leptin relates to prolonged cardiovascular recovery after acute stress in Africans: The SABPA study. Nutr Metab Cardiovasc Dis. 2016;26(1):45-52. DOI: 10.1016/j.numecd.2015.10.014
  • Puurunen VP, Kiviniemi A, Lepojärvi S, et al. Leptin predicts short-term major adverse cardiac events in patients with coronary artery disease. Ann Med. 2017;49(5):448-454. DOI: 10.1080/07853890.2017.1301678
  • Hasan-Ali H, Abd El-Mottaleb NA, Hamed HB, Abd-Elsayed A. Serum adiponectin and leptin as predictors of the presence and degree of coronary atherosclerosis. Coron Artery Dis. 2011;22(4):264-269. DOI: 10.1097/MCA.0b013e3283452431
  • Amasyali B, Aytemir K, Kose S, et al. Admission plasma leptin level strongly correlates with the success of thrombolytic therapy in patients with acute myocardial infarction. Angiology. 2006;57(6):671-680. DOI: 10.1177/0003319706295204
  • Takahashi Y, Satoh M, Tabuchi T, Nakamura M. Prospective, randomized, single-blind comparison of effects of 6 months’ treatment with atorvastatin versus pravastatin on leptin and angiogenic factors in patients with coronary artery disease. Heart Vessels. 2012;27(4):337-343. DOI: 10.1007/s00380-011-0156-y
  • Katsiki N, Mikhailidis DP, Gotzamani-Psarrakou A, et al. Effect of various treatments on leptin, adiponectin, ghrelin and neuropeptide Y in patients with type 2 diabetes mellitus. Expert Opin Ther Targets. 2011;15(4):401-420. DOI: 10.1517/14728222.2011.553609
  • Zhao S, Zhu Y, Schultz RD, et al. Partial Leptin Reduction as an Insulin Sensitization and Weight Loss Strategy. Cell Metab. 2019;30(4):706-719.e6. DOI: 10.1016/j.cmet.2019.08.005
  • Ben-Zvi D, Savion N, Kolodgie F, et al. Local Application of Leptin Antagonist Attenuates Angiotensin II-Induced Ascending Aortic Aneurysm and Cardiac Remodeling. J Am Heart Assoc. 2016;5(5):e003474. DOI: 10.1161/JAHA.116.003474
  • Roujeau C, Jockers R, Dam J. New pharmacological perspectives for the leptin receptor in the treatment of obesity. Front Endocrinol (Lausanne). 2014;5:167. DOI: 10.3389/fendo.2014.00167
  • Crujeiras AB, Carreira MC, Cabia B, et al. Leptin resistance in obesity: An epigenetic landscape. Life Sci. 2015;140:57-63. DOI: 10.1016/j.lfs.2015.05.003
  • Park HK, Ahima RS. Physiology of leptin: energy homeostasis, neuroendocrine function and metabolism. Metabolism. 2015;64(1):24-34. DOI: 10.1016/j.metabol.2014.08.004
  • DePaoli AM. 20 years of leptin: leptin in common obesity and associated disorders of metabolism. J Endocrinol. 2014;223(1):T71-T81. DOI: 10.1530/JOE-14-0258
  • Feng X, Guan D, Auen T, et al. IL1R1 is required for celastrol’s leptin-sensitization and antiobesity effects. Nat Med. 2019;25(4):575-582. DOI: 10.1038/s41591-019-0358-x
  • Lee J, Liu J, Feng X, et al. Withaferin A is a leptin sensitizer with strong antidiabetic properties in mice. Nat Med. 2016;22(9):1023-1032. DOI: 10.1038/nm.4145
  • Zhao S, Kusminski CM, Scherer PE. Adiponectin, Leptin and Cardiovascular Disorders. Circ Res. 2021;128(1):136-149. DOI: 10.1161/CIRCRESAHA.120.314458
  • Zaletel J, Barlovic DP, Prezelj J. Adiponectin-leptin ratio: a useful estimate of insulin resistance in patients with Type 2 diabetes. J Endocrinol Invest. 2010;33(8):514-518. DOI: 10.1007/BF03346639
  • López-Jaramillo P, Gómez-Arbeláez D, López-López J, et al. The role of leptin/adiponectin ratio in metabolic syndrome and diabetes. Horm Mol Biol Clin Investig. 2014;18(1):37-45. DOI: 10.1515/hmbci-2013-005377.
  • Selthofer-Relatić K, Radić R, Stupin A, et al. Leptin/adiponectin ratio in overweight patients - gender differences. Diab Vasc Dis Res. 2018;15(3):260-262. DOI: 10.1177/1479164117752491
  • Vega GL, Grundy SM. Metabolic risk susceptibility in men is partially related to adiponectin/leptin ratio. J Obes. 2013;2013:409679. DOI: 10.1155/2013/409679
  • Frühbeck G, Catalán V, Rodríguez A, et al. Adiponectin-leptin Ratio is a Functional Biomarker of Adipose Tissue Inflammation. Nutrients. 2019;11(2):454. DOI: 10.3390/nu11020454
  • Frühbeck G, Catalán V, Rodríguez A, Gómez-Ambrosi J. Adiponectin-leptin ratio: A promising index to estimate adipose tissue dysfunction. Relation with obesity-associated cardiometabolic risk. Adipocyte. 2018;7(1):57-62. DOI: 10.1080/21623945.2017.1402151
Еще
Статья обзорная
SciUp 2024 © 2024 ©